HK1005456A1 - Azasteroid compounds for the treatment of prostatic hypertrophy their preparation and use - Google Patents

Azasteroid compounds for the treatment of prostatic hypertrophy their preparation and use

Info

Publication number
HK1005456A1
HK1005456A1 HK98104572A HK98104572A HK1005456A1 HK 1005456 A1 HK1005456 A1 HK 1005456A1 HK 98104572 A HK98104572 A HK 98104572A HK 98104572 A HK98104572 A HK 98104572A HK 1005456 A1 HK1005456 A1 HK 1005456A1
Authority
HK
Hong Kong
Prior art keywords
alkyl group
substituted alkyl
carbon
preparation
treatment
Prior art date
Application number
HK98104572A
Other languages
English (en)
Inventor
Koichi Kojima
Hitoshi Kurata
Hiroyoshi Horikoshi
Takakazu Hamada
Original Assignee
Sankyo Co
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Sankyo Co filed Critical Sankyo Co
Publication of HK1005456A1 publication Critical patent/HK1005456A1/xx

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07J—STEROIDS
    • C07J73/00—Steroids in which the cyclopenta[a]hydrophenanthrene skeleton has been modified by substitution of one or two carbon atoms by hetero atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07J—STEROIDS
    • C07J73/00—Steroids in which the cyclopenta[a]hydrophenanthrene skeleton has been modified by substitution of one or two carbon atoms by hetero atoms
    • C07J73/001—Steroids in which the cyclopenta[a]hydrophenanthrene skeleton has been modified by substitution of one or two carbon atoms by hetero atoms by one hetero atom
    • C07J73/005—Steroids in which the cyclopenta[a]hydrophenanthrene skeleton has been modified by substitution of one or two carbon atoms by hetero atoms by one hetero atom by nitrogen as hetero atom
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/58—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids containing heterocyclic rings, e.g. danazol, stanozolol, pancuronium or digitogenin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/02—Drugs for disorders of the urinary system of urine or of the urinary tract, e.g. urine acidifiers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/08—Drugs for disorders of the urinary system of the prostate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/24—Drugs for disorders of the endocrine system of the sex hormones

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Urology & Nephrology (AREA)
  • Endocrinology (AREA)
  • Diabetes (AREA)
  • Reproductive Health (AREA)
  • Epidemiology (AREA)
  • Steroid Compounds (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
HK98104572A 1990-10-29 1998-05-27 Azasteroid compounds for the treatment of prostatic hypertrophy their preparation and use HK1005456A1 (en)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
JP29140190 1990-10-29

Publications (1)

Publication Number Publication Date
HK1005456A1 true HK1005456A1 (en) 1999-01-08

Family

ID=17768420

Family Applications (2)

Application Number Title Priority Date Filing Date
HK98104572A HK1005456A1 (en) 1990-10-29 1998-05-27 Azasteroid compounds for the treatment of prostatic hypertrophy their preparation and use
HK99102601A HK1017274A1 (en) 1990-10-29 1999-06-17 Process for the preparation of pharmaceutical composition containing azasteroid compounds for the treatment of prostatic hypertrophy

Family Applications After (1)

Application Number Title Priority Date Filing Date
HK99102601A HK1017274A1 (en) 1990-10-29 1999-06-17 Process for the preparation of pharmaceutical composition containing azasteroid compounds for the treatment of prostatic hypertrophy

Country Status (20)

Country Link
US (1) US5302621A (ko)
EP (1) EP0484094B1 (ko)
JP (1) JPH0819151B2 (ko)
KR (1) KR0134570B1 (ko)
CN (2) CN1053672C (ko)
AT (1) ATE139783T1 (ko)
AU (1) AU640279B2 (ko)
CA (1) CA2054368C (ko)
CZ (1) CZ279312B6 (ko)
DE (1) DE69120500T2 (ko)
DK (1) DK0484094T3 (ko)
ES (1) ES2091299T3 (ko)
GR (1) GR3020483T3 (ko)
HK (2) HK1005456A1 (ko)
HU (2) HU218667B (ko)
IE (1) IE76452B1 (ko)
IL (1) IL99889A (ko)
PT (1) PT99371B (ko)
RU (1) RU2070204C1 (ko)
ZA (1) ZA918570B (ko)

Families Citing this family (38)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5304562A (en) * 1991-10-09 1994-04-19 Ciba-Geigy Corporation 17β-substituted Aza-androstane derivatives
CA2084799C (en) 1991-12-17 2003-01-28 Glenn J. Gormley Method of prevention of prostatic carcinoma with 17 beta-n-monosubstituted-carbamoyl-4-aza-5 alpha-androst-1 -en-3-ones
WO1993013124A1 (en) * 1991-12-20 1993-07-08 Glaxo Inc. Inhibitors of 5-alpha-testosterone reductase
US5698720A (en) * 1992-04-20 1997-12-16 Sankyo Company, Limited Steroid derivatives
EP0725074A3 (en) * 1992-04-20 1996-11-20 Sankyo Co Compounds for use, therefore, intermediates for the preparation of androst-3,5-diene-3-carboxy derivatives
US5710275A (en) * 1992-05-20 1998-01-20 Merck & Co., Inc. 7β-substituted-4-aza-5α-androstan-3-ones as 5α-reductase inhibitors
CA2135167A1 (en) * 1992-05-20 1993-11-25 Donald W. Graham New 17-ester, amide, and ketone derivatives of 3-oxo-4- azasteroids as 5a-reductase inhibitors
GB9216284D0 (en) * 1992-07-31 1992-09-16 Erba Carlo Spa Fluorinated 17beta-substituted 4-aza-5alpha-androstane-3-one derivatives
GB9216329D0 (en) * 1992-07-31 1992-09-16 Erba Carlo Spa 17beta-substituted 4-aza-5alpha-androstan-3-one derivatives
US5302589A (en) * 1992-08-07 1994-04-12 Glaxo, Inc. Heterocyclic inhibitors of 5-α-testosterone reductase
HU212459B (en) * 1992-10-02 1996-06-28 Richter Gedeon Vegyeszet Process for producing new 17-beta-substituted 4-aza-androstane-derivatives and pharmaceutical compositions containing them
DE69329933T2 (de) * 1992-10-06 2001-07-19 Merck & Co Inc 17-beta-carboxanilid derivate von 4-aza-5-alpha-androstan-3-one als 5-alpha-reduktase-hemmende arzneimittel
WO1994022900A1 (en) * 1993-04-02 1994-10-13 Ciba-Geigy Ag AZA-ANDROSTANE-17β-CARBOXAMIDES
TW369521B (en) * 1993-09-17 1999-09-11 Smithkline Beecham Corp Androstenone derivative
TW408127B (en) * 1993-09-17 2000-10-11 Glaxo Inc Androstenones
EP0748221B1 (en) * 1993-11-04 1999-04-14 Merck & Co. Inc. 7-substituted-4-aza-steroid derivatives as 5-alpha- reductase inhibitors
US5817818A (en) * 1994-09-16 1998-10-06 Glaxo Wellcome Inc. Androstenones
US5578724A (en) * 1994-09-20 1996-11-26 Eli Lilly And Company Process for preparation of benzo[f]quinolinones
US5541322A (en) * 1994-10-14 1996-07-30 Glaxo Wellcome Inc. Synthesis of 6-azaandrostenones
US5543417A (en) * 1994-10-21 1996-08-06 Merck & Co., Inc. Combination method of treating acne using 4-AZA-5α-cholestan-ones and 4-AZA-5α-androstan-ones as selective 5α-reductase inhibitors with anti-bacterial, keratolytic, or anti-inflammatory agents
IT1271325B (it) * 1994-12-23 1997-05-27 Poli Ind Chimica Spa Composti diastereomericamente puri derivati da 3-oxo e 3-tioxo-4-azaandrostani e loro uso come antiandrogeni
US5656613A (en) * 1995-01-04 1997-08-12 Merck & Co., Inc. Treatment of hyperandrogenic conditions
CN1072679C (zh) * 1995-07-30 2001-10-10 重庆医科大学 一种氮杂甾体化合物、制备及其用途
USRE39056E1 (en) * 1995-09-15 2006-04-04 Merck & Co, Inc. 4-Azasteroids for treatment of hyperandrogenic conditions
JPH11512434A (ja) * 1995-09-15 1999-10-26 メルク エンド カンパニー インコーポレーテッド アンドロゲン過剰状態治療用の４−アザステロイド
HUP9901870A3 (en) * 1996-02-05 1999-11-29 Sankyo Company Ltd Chuo Ku 5alfa-reductase inhibitory preparation for oral administration, process for producing the same, and use thereof
US6093722A (en) 1997-02-26 2000-07-25 Sankyo Company, Limited Method for treating prostate cancer
ATE265854T1 (de) * 1997-02-26 2004-05-15 Sankyo Co Azasteroidverbindung zur behandlung oder vorbeugung von prostatakrebs
ES2218840T3 (es) * 1997-07-29 2004-11-16 Sankyo Company Limited Composicion azasteroide para ael tratamiento de la alopecia, el hirsutismo femenino y la seborrea.
US6187925B1 (en) * 1997-12-23 2001-02-13 Merck & Co., Inc. Intermediates and process for the synthesis of azasteroids
US5998427A (en) * 1998-05-14 1999-12-07 Glaxo Wellcome Inc. Androstenones
US6645974B2 (en) 2001-07-31 2003-11-11 Merck & Co., Inc. Androgen receptor modulators and methods for use thereof
AU2004238238C1 (en) * 2003-05-07 2010-01-14 Merck Sharp & Dohme Corp. Androgen receptor modulators and methods of use thereof
WO2005009949A2 (en) * 2003-06-30 2005-02-03 Merck & Co., Inc. 17-acetamido-4-azasteroid derivatives as androgen receptor modulators
US7482357B2 (en) * 2003-06-30 2009-01-27 Merck & Co., Inc. 17-acetamido-4-azasteroid derivatives as androgen receptor modulators
AU2004256075B2 (en) * 2003-06-30 2008-12-04 Merck Sharp & Dohme Corp. 17-acetamido-4-azasteroid derivatives as androgen receptor modulators
WO2005097127A2 (en) * 2004-04-02 2005-10-20 Merck & Co., Inc. Method of treating men with metabolic and anthropometric disorders
AU2006229840B2 (en) * 2005-03-25 2010-12-23 Merck Sharp & Dohme Corp. Method of treating men with testosterone supplement and 5alpha-reductase inhibitor

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4179453A (en) 1978-04-13 1979-12-18 Merck & Co., Inc. Process for preparing 17β-carboxy-5-androsten-3-ones
AU527030B2 (en) * 1978-04-13 1983-02-10 Merck & Co., Inc. 4-aza-17-substituted-5a-androstan-3-ones
US4377584A (en) * 1978-04-13 1983-03-22 Merck & Co., Inc. 4-Aza-17β-substituted-5α-androstan-3-one-reductase inhibitors
US4220775A (en) * 1979-03-15 1980-09-02 Merck & Co., Inc. Preparation of 4-aza-17-substituted-5α-androstan-3-ones useful as 5α-reductase inhibitors
IL74365A (en) * 1984-02-27 1990-07-26 Merck & Co Inc 17beta-(n-t.-butylcarbamoyl)-4-aza-5alpha-androst-1-en-3-one and pharmaceutical compositions containing it
US4760071A (en) 1984-02-27 1988-07-26 Merck & Co., Inc. 17β-N-monosubstituted carbamoyl-4-aza-5α-androst-1-en-3-ones which are active as testosterone 5α-reductase inhibitors
GB8505862D0 (en) * 1985-03-07 1985-04-11 Erba Farmitalia Steroidic 5alpha-reductase inhibitors
US5021575A (en) * 1989-11-13 1991-06-04 Merck & Co., Inc. Method for introducing a 1,2 double bond into azasteroids

Also Published As

Publication number Publication date
EP0484094A2 (en) 1992-05-06
AU640279B2 (en) 1993-08-19
HU913396D0 (en) 1992-01-28
KR920008063A (ko) 1992-05-27
IE76452B1 (en) 1997-10-22
HU218667B (hu) 2000-10-28
DK0484094T3 (da) 1996-10-28
CS326991A3 (en) 1992-05-13
IL99889A0 (en) 1992-08-18
CA2054368C (en) 2001-10-02
HU211642A9 (en) 1995-12-28
CN1209319A (zh) 1999-03-03
IE913747A1 (en) 1992-05-22
EP0484094B1 (en) 1996-06-26
US5302621A (en) 1994-04-12
ES2091299T3 (es) 1996-11-01
EP0484094A3 (en) 1993-07-14
CN1053672C (zh) 2000-06-21
PT99371A (pt) 1992-09-30
CA2054368A1 (en) 1992-04-30
ZA918570B (en) 1992-08-26
PT99371B (pt) 1999-04-30
ATE139783T1 (de) 1996-07-15
GR3020483T3 (en) 1996-10-31
CN1072935C (zh) 2001-10-17
JPH0532693A (ja) 1993-02-09
RU2070204C1 (ru) 1996-12-10
CZ279312B6 (cs) 1995-04-12
KR0134570B1 (ko) 1998-04-14
IL99889A (en) 1995-06-29
AU8682191A (en) 1992-04-30
CN1062145A (zh) 1992-06-24
DE69120500T2 (de) 1997-02-27
DE69120500D1 (de) 1996-08-01
JPH0819151B2 (ja) 1996-02-28
HUT59417A (en) 1992-05-28
HK1017274A1 (en) 1999-11-19

Similar Documents

Publication Publication Date Title
ZA918570B (en) Azasteroid compounds for the treatment of prostatic hypertrophy,their preparation and use
AU588972B2 (en) New derivatives of 1,2,5,6-tetrahydropyridine-3- carboxaldehyde oxime, their preparation process, their use as medicaments, and the compositions containing them
HU9301155D0 (en) Methods for producing steroide derivatives and for their application in medical treatment
AU586691B2 (en) Diamino-androstane derivatives, process for their preparation and pharmaceutical compositions containing them
MY100095A (en) 2-oxo-imidazolidine compounds, a process for preparing the same and a pharmaceutical composition.
CA2010982A1 (en) Osteogenesis promotion with use of vitamin d derivatives
TW225989B (ko)
HU905000D0 (en) Process for producing compounds suitable for treatment of gastric ulcer
AU2742288A (en) Novel compound effective as cerebral insufficiency improver
DK0627419T3 (da) Optisk aktive derivater af 1-phenylpyrrolidon og fremgangsmåde til fremstilling deraf
EP0441116A3 (en) Optically active chroman derivatives and intermediates thereof, and process for manufacturing same

Legal Events

Date Code Title Description
PF Patent in force
PC Patent ceased (i.e. patent has lapsed due to the failure to pay the renewal fee)

Effective date: 20051029